Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can early blood tests predict Five-Year kidney transplant success?

NCT ID NCT01974999

Knowledge-focused Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are reviewing medical records from 184 people who received kidney transplants and took part in an earlier immune-monitoring study. The goal is to see whether blood test results from the first six months after transplant can predict kidney function, graft survival, and patient survival five years later. Each participating center will collect data on estimated glomerular filtration rate, deaths, and graft loss. The study tests whether a noninvasive monitoring strategy could one day help doctors identify patients at risk of long-term complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the early immune monitoring strategy proves predictive, doctors could one day use simple blood tests to spot transplant patients at risk of long-term kidney decline and adjust care earlier.
What could go wrong
This is a small retrospective review of 184 people, so it can only show patterns, not cause and effect. The findings may not apply to other transplant centers or newer immunosuppressive regimens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

184 people

The number who actually took part.

Start date

Oct 2013

Finished

Jul 2014

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population was selected based on their previous participation in the parent study (CTOT-01). A total of 280 subjects were enrolled and transplanted in the Clinical Trials in Organ Transplantation

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants previously enrolled in the CTOT-01 study. * Participants who are at least 5 years post-transplant (+/- 6 months), no later than March 31, 2014. Exclusion Criteria: * Withdrawal of consent to continue in the CTOT-01 study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage renal disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure impaired renal function disease kidney disorder kidney failure Rejection, Psychology

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage renal disease Kidney disease Kidney failure

Contacts and locations

Locations

  • Children's Hospital of Winnipeg

    Winnipeg, Manitoba, Canada

  • Cleveland Clinic Foundation, Glickman Urological Institute

    Cleveland, Ohio, 44195, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Mount Sinai School of Medicine

    New York, New York, 10029, United States

  • University Hospitals of Cleveland

    Cleveland, Ohio, 44106, United States

  • University of Manitoba Health Sciences Centre

    Winnipeg, Manitoba, R3A 1R9, Canada

  • Yale University School of Medicine

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.